Article Text
Abstract
Parkinson’s disease is the second most common neurodegenerative disorder in developed countries, after Alzheimer’s disease, with an estimated prevalence of three patients per 1000 population. The diagnosis is not always easy because it is mostly based on the clinical features that are in part present in several other akinetic rigid syndromes. Moreover, there are no reliable biological markers for confirmation of the disease and nor for the differential diagnosis between the several disorders that can present with the same core syndrome. In fact, there are frequent errors in clinical diagnosis as shown in clinico-pathological series, even in up to 25% of patients regularly examined up to the time of their death by neurologists well-experienced with the disease (Hughes et al. 1992).
Several studies in Europe and other parts of the world have shown there is great discrepancy between the prevalence of Parkinson’s disease in different geographical areas depending on whether
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism
- Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study
- 123I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease: a new quantitative analysis of autopsy confirmed cases
- A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes
- Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease
- Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease
- Parkinson's disease: chameleons and mimics
- Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes
- Both total and phosphorylated tau are increased in Alzheimer's disease
- Open questions on the nature of Parkinson’s disease: from triggers to spreading pathology